Benzinga | Jul 23, 2021 08:03AM EDT

Cortexyme Selects 3CLpro Inhibitor COR803 For Treatment Of Coronavirus Infection

Cortexyme, Inc. (NASDAQ:CRTX), a company advancing a pivotal trial in Alzheimer's disease with top-line data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, announced the selection of a lead 3CLpro inhibitor (COR803) for treatment of coronavirus infections, including COVID-19 disease, caused by SARS-CoV-2 infection.